secwatch.observer — SEC 8-K summary
======================================

Issuer:     Y-mAbs Therapeutics, Inc. (—)
CIK:        0001722964
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001558370-25-000105
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Y-mAbs realigns into two units, cuts ~13% staff; FY24 rev ~$88M; GD2-SADA data Q2 2025
--------------------------------------------------------------------------------

- Preliminary FY2024 total net revenue ~$88M (guidance $87-95M); cash ~$67M; cash investment ~$11M (below $15-20M guidance).
- Workforce reduction of up to ~13% as part of realignment into DANYELZA and Radiopharmaceutical business units.
- SVP/Chief Commercial Officer Susan Smith departs April 9, 2025; Doug Gentilcore named SVP Danyelza Unit Head, Natalie Tucker promoted to SVP Radiopharma Head.
- GD2-SADA Phase 1 Part A (21 patients) well-tolerated, no DLTs; Part A data expected in Q2 2025.
- CD38-SADA first patient dosing expected Q1 2025; potential DANYELZA ex-US approval in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1722964/000155837025000105/0001558370-25-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1722964/000155837025000105/ymab-20250106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer